AbbVie Announces $380 Million Expansion of API Manufacturing in North Chicago
Introduction:
AbbVie has revealed plans to invest $380 million to expand its active pharmaceutical ingredient (API) production capabilities at its North Chicago campus. The initiative involves constructing two state-of-the-art manufacturing facilities designed to support the development of next-generation treatments, with a particular focus on neuroscience and obesity therapies.
Features:
The upcoming facilities will integrate advanced manufacturing technologies and artificial intelligence to enhance both efficiency and accuracy throughout the production process.
APIs, which are the core components that provide the therapeutic effect in medicines, require intricate multi-step chemical synthesis for their creation.
The expansion is projected to generate approximately 300 new jobs in North Chicago, including roles for engineers, scientists, lab technicians, and manufacturing operators.
Earlier, in September 2025, AbbVie began the first phase of the project by constructing a new chemical synthesis facility.
This facility aims to relocate some API production for neuroscience, immunology, and oncology medicines from Europe and Asia back to the United States.
The two new API manufacturing facilities are expected to be fully operational by 2029.
Specifications
| Name | AbbVie |
| Budget | $380 Million |
| Type | Expansion |
| Year of Completion | 2029 |
